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Abstract: 
Background  
Trials of investigational medicinal products are required to adhere to strict 
guidelines with regard to the handling and supply of medication. 
Information technology offers opportunities to approach clinical trial 
methodology in new ways. This report summarises a novel pharmacy 
system designed to supply trial medications directly to patients by post in 
the Febuxostat versus Allopurinol Streamlined Trial (FAST).  
Method  
A bespoke web-based software package was designed to facilitate the 
direct supply of trial medications to FAST participants from a pharmacy 
based in the Medicines Monitoring Unit (MEMO), University of Dundee.  
Results  
To date, 65467 packs of medication have been dispensed using the system 
to 3978 patients.  Up to 238 packs per day have been dispensed.  
Conclusions  
The Medicines Monitoring Unit FAST Drug Management System is an 
effective method of administering the complex drug supply requirements of 
a large scale clinical trial with advantages over existing arrangements. A 
low rate of loss to follow-up in the FAST trial may be attributable to the 
drug management system.  
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Abstract 
Background: Trials of investigational medicinal products are required to adhere to strict 
guidelines with regard to the handling and supply of medication. Information technology 
offers opportunities to approach clinical trial methodology in new ways. This report 
summarises a novel pharmacy system designed to supply trial medications directly to 
patients by post in the Febuxostat versus Allopurinol Streamlined Trial (FAST). 
Method: A bespoke web-based software package was designed to facilitate the direct 
supply of trial medications to FAST participants from a pharmacy based in the Medicines 
Monitoring Unit (MEMO), University of Dundee. 
Results: To date, 65,467 packs of medication have been dispensed using the system to 
3,978 patients. Up to 238 packs per day have been dispensed. 
Conclusions: The Medicines Monitoring Unit FAST drug management system is an 
effective method of administering the complex drug supply requirements of a large scale 
clinical trial with advantages over existing arrangements. A low rate of loss to follow-up 
in the FAST trial may be attributable to the drug management system. 
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Background 
Information technology offers opportunities to approach clinical trial methodology in 
new ways. This report summarises a novel pharmacy system designed to supply trial 
medications directly to patients in a primary care setting. Primary care-based clinical 
trials aim to provide answers with high external validity. However, conducting research 
in primary care has its own challenges. Recruitment and retention of general practitioners 
and their patients are significant rate limiting steps in the process of conducting a trial.
1
Minimising the potential financial and time burden on trial participants may increase 
recruitment and retention.
2
 Trials of investigational medicinal products are required to
adhere to strict guidelines with regard to the handling and supply of medication.
3
 A
systematic literature search on the subject (online Supplementary Material 1) found only 
2 reports of computerised investigational drug services set up in secondary and tertiary 
care facilities in North America.
4, 5
 The search failed to uncover reports of any similar
systems designed for use in primary care research. The FAST study team have developed 
a system to streamline the handling of study drug that could be used as a model for other 
future drug trials. 
Methods 
The Febuxostat versus Allopurinol Streamlined Trial (FAST) is a prospective, 
randomised, open-label, blinded endpoint evaluation trial to compare the cardiovascular 
safety of febuxostat and allopurinol in patients with a diagnosis of gout.
6, 7
 The pragmatic
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design allows the safety of the two drugs to be compared while permitting dose 
adjustments during the study, if required, usually for clinical reasons. Recruited patients 
in the UK and Denmark are randomised to receive either allopurinol or febuxostat along 
with medication for gout flare prophylaxis. The gout flare prophylaxis is supplied if 
required, in accordance with European League Against Rheumatism recommendations 
and is available in 4 forms: colchicine; naproxen with omeprazole or ranitidine; 
meloxicam with omeprazole or ranitidine; or diclofenac with omeprazole or ranitidine.
8
(figure 1) 
Medication supply is standardised across all centres taking part in this study. 
Patients recruited from all study centres are supplied their medication directly from a pre-
approved registered pharmacy premises run by the Medicines Monitoring Unit at 
Ninewells Hospital, Dundee, UK. The study medication is supplied by post at regular 
intervals. 
All FAST study medication is received, stored, labelled and distributed from the 
Medicines Monitoring Unit Pharmacy dispensary. A number of facilities are in place to 
allow this: (i) a temperature-controlled bulk-store (capable of storing 23m
3
 or 18 pallets
of investigational medicinal product); (ii) a temperature-controlled “buffer” store in the 
Hypertension; and (iii) an adjacent Medicines Monitoring Unit dispensary. 
Nurses inform the dispensary by email when they have seen a patient at a follow-
up appointment who requires a change to medication according to the study protocol. The 
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dispensary then accesses that patient’s details via a pharmacy web portal and can 
determine what medications are required along with required information such as 
delivery addresses and their doctor’s contact details. The order is then generated and 
filled ready for Royal Mail first class delivery. All medications are supplied in “mail 
friendly” packaging containing a study-specific bilingual (English & Danish) patient 
information leaflet with details of the relevant medication. The format and information 
contained is very similar to those provided with commercially available packs of these 
medicines. 
The FAST drug management system 
This bespoke software program tracks the stock of investigational medicinal products 
(allopurinol and febuxostat) and non-investigational medicinal products (gout flare 
prophylaxis medications and concomitant gastric protectants) used throughout the trial. 
The system controls drug supply management for patients in the FAST study. 
The FAST drug management administrative system is web-based with real-time 
updating of stock levels and dispensing details. The system is used exclusively by staff 
engaged in the FAST trial. The key users are the trial superintendent pharmacist, a 
research pharmacist(s), and pharmacy technicians. 
During development, the Microsoft Internet Explorer 9 browser was identified as 
the single platform for the interface, eliminating the need to target multiple browsers. 
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(More specific information about the hosting requirements of the system can be found in 
online Supplementary Material 2.) 
All aspects of the drug supply process are automatically recorded on the FAST 
drug management system allowing an audit trail to be established. 
User interface. The user interface of the FAST drug management system is a web 
application. Once a user is logged in, seven main areas of functionality are available to 
them: shipping, confirmation, dispensing, check, receipts, returns, and stock. A restricted 
access area is also available to the superintendent pharmacist that allows the creation of 
new system users. The user interface allows stock level monitoring. This facilitates 
simple spot checks and allows stock levels to be monitored and maintained. 
Shipping and confirmation. When a new consignment of medication arrives on site, 
details of the shipping are entered into the user interface and the database is updated 
automatically. Each medication pack that arrives is assigned a unique barcode for use 
within the FAST drug management system. The confirmation page of the user interface 
then requires a second operator to confirm the details of the newly arrived medication 
before it is recognized as in stock and available for dispensing. 
Dispensing, checking and receipts. Medicines are dispensed with the addition of a 
dispensing label which includes the medicine name, patient name, date of supply, 
standard safety warnings, the center-specific investigator’s name and an instruction to 
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“use as directed on the patient direction form”. Patients are also supplied with a patient 
direction form, a receipt of supply form and a prepaid return mail polybag. All items 
issued to patients are barcoded to enable the subsequent dispensing check and to track 
returned receipt postcards and patient returned medication. 
On selecting a patient, the required address labels are automatically printed (based 
on the number of packs of study medication required). The required medications for that 
patient are displayed on screen. The receipt postcard is scanned by the pharmacy 
technician followed by each medication pack in turn. Each product barcode is checked by 
the system to confirm that the correct product has been selected and to check that the 
product will not expire within 2 months of dispensing. Each time a suitable pack is 
scanned a dispensing label is automatically printed and immediately stuck to the pack. 
(figure 2) 
A second dispensing stage requires another operative (pharmacist or pharmacy 
technician) to verify the medication packs selected by the initial user. This is done by 
scanning the box barcodes and comparing the boxes with the expected content products 
displayed. If the barcodes scan correctly, indicating that the pack(s) has been correctly 
assembled, and the second operative is satisfied that the products are correct, the 
dispensing is confirmed. The box is then considered “sent”. All medications delivered to 
patients are supplied with a postage-paid postcard that acts as a receipt. Returned receipt 
postcards are scanned and recorded in the system. 
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Patients are asked to return any unused medication from their previous delivery in 
the polybag provided. Returned product is logged by scanning the product pack barcode 
and entering the number of pills returned within. 
Medication considerations in FAST 
Medicines used in FAST are the investigational medicinal products: allopurinol, 
febuxostat; and the non-investigational medicinal products, used for gout flare 
prophylaxis and gastric protection: colchicine, naproxen, diclofenac, meloxicam, 
omeprazole and ranitidine. These medications are received from two different sources. 
Investigational medicinal products and some non-investigational medicinal products are 
supplied by the trial funder. The remainder of the non-investigational medicinal products 
are procured independently (via wholesale or local hospital pharmacy). The FAST drug 
management system allows these two different source pathways to be managed within 
one trial-specific system. 
Results 
At the time of writing, 65,467 packs of medication have been dispensed using the system 
to 3,978 patients. Up to 238 packs per day have been dispensed. During a 20 month 
analysis period, 25,568 supplies were made to patients in the UK and Denmark, 
comprising 38,250 individual packages. Only 46 of these were reported as failing to 
arrive, the majority of which had simply been delayed in transit. Only 8 packages could 
be considered lost during this 20 month period (0.31 per 1000 dispatched packages). 
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Initial supplies of study medication are mailed to participants on the day of randomisation 
and arrive within 1-2 days in the UK. Deliveries to Denmark have been predictably 
slower but arrive well within the 21 days required by the FAST study protocol. 
Subsequent repeat medication supplies are sent out a minimum of 8 days before they are 
required with additional time allowed for international delivery and busy postal periods 
e.g. Christmas. 
A lack of unaccountable loss to follow-up of patients within FAST in the 3.5 
years since the trial began may be attributable to the regular prompting that direct 
medication delivery provides. There have been 133 withdrawals from study treatment 
after randomisation in the same period (out of 3130 randomised) suggesting that 
participant acceptability of the drug delivery system compares favourably with more 
traditional methods. 
Conclusions 
The FAST drug management system has a number of advantages over more standard 
methods of clinical trial drug supply and distribution. The use of computer technology 
allows real-time monitoring of stock levels for the whole study at a glance. This reduces 
the chance of any stock problems interfering with the correct administration of 
medication according to study protocol. Direct supply of study drug to participants 
removes the requirement for study drug storage at multiple sites. This single central 
storage location thus allows efficiency savings in equipment, personnel and training. The 
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FAST drug management system was set-up to accept supply of study drug from more 
than one source. This could be scaled up to coordinate multiple drug sources for more 
complex trial requirements. The software adheres to European Union regulatory 
requirements for labeling of dispensed medication and can be simply modified to allow 
dispensing to non-English speaking trial participants. It is recognized, though, that non-
Roman script would require more intensive software adaptation. 
As participants in the FAST study receive their study medication directly to their 
home address they benefit from the convenience of post-box compatible delivery and the 
removal of the need to regularly visit a dispensing site throughout the study period. The 
system database can easily accommodate changes in address should participants move 
home during a lengthy study period. The use of individually barcoded packs and the 
printing of predetermined text which draws on patient details taken from the electronic 
case report form mean that dispensing errors are minimised. 
Further research is ongoing into the potential cost savings of alternative supply 
mechanisms aiming to further reduce the amount of drug oversupply. 
Discussion 
As with any successful organizational change, the implementation of the FAST drug 
management system was borne out of a consensus agreement that a new way of handling 
study drug was required. Overcoming resistance to change relied on regular 
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communication between involved parties, and effective leadership to steer alterations to 
normal practice.  The presence of an in-house software development team was 
fundamental in allowing the development of a system to meet the specific requirements 
of clinical trial study drug management. 
The FAST drug management software is currently closed source and owned by 
The University of Dundee. Researchers wishing to produce such a system would require 
a software development team, working closely with pharmacy staff, and, a systems 
administrator to ensure smooth running and back-up. 
Minimising missing data is important in any study. Long duration trials like 
FAST are particularly susceptible to loss to follow-up and withdrawals. We are 
encouraged that withdrawals from the trial so far have been relatively low when 
compared to the 6% median and 2-14% interquartile range reported by LOST-IT review.
9
While the FAST study used investigational medicinal product, the system would 
also be capable of supplying licensed drugs in post-marketing studies. A facility to 
privately prescribe and dispense licensed medications that are not yet approved for 
National Health Service use could simplify post-marketing research. 
The FAST drug management system has been demonstrated to be a safe and 
effective method of administering the complex drug supply requirements of a large scale 
Page 12 of 19
Journal of the Society for Clinical Trials
Clinical Trials
clinical trial. We propose that it can be used as a prototype in developing future clinical 
trials. 
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Figure legend 
Figure 1. FAST study flow diagram 
Figure 2. FAST drug management system process diagram 
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Febuxostat  
• Dose optimised 
• Adjustments as clinically
necessary 
• Initiation of gout flare 
prophylaxis for 6 months, if
required. 
Allopurinol 
• Dose as before 
randomisation. 
• Adjustments as clinically
necessary 
• Initiation of gout flare 
prophylaxis for 6 months, if
required. 
Informed Consent and 
Screening 
Randomisation 
Allopurinol lead-in phase: 
• Allopurinol dose 
optimisation 
• Initiation of gout 
flare prophylaxis for 
6 months, if required 
One week washout period  
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FAST DMS Supplementary Material 1 
Pubmed Systematic Literature Search Strategy 
MeSH headings and keywords were determined using the NIH MeSH on demand website to analyse 
a description of the FAST DMS.  (http://www.nlm.nih.gov/mesh/MeSHonDemand.html) 
1. Search (((((clinical trials as topic[MeSH Major Topic]) OR "clinical trial"[Title/Abstract]) OR
 "drug trial"[Title/Abstract]) OR "randomised controlled trial"[Title/Abstract])) OR 
research[Title/Abstract] 
= 1038326 items found 
2. Search ((((("drugs, investigational/supply and distribution"[MeSH Major Topic])) OR
"pharmaceutical services"[MeSH Major Topic]) OR "medicines management"[Title/Abstract]) OR 
"drug management"[Title/Abstract]) AND "pharmacy"[Title/Abstract] 
=7555 items found 
3. Search (((("online systems"[MeSH Major Topic]) OR "electronic mail"[MeSH Major Topic])
OR
"postal service"[MeSH Major Topic]) OR "online"[Title/Abstract]) OR "web-based"[MeSH Major 
Topic] 
=55229 items found 
4. Search ((#11) AND #18) AND #19
=29 items found 
Date searched 2
nd
 June 2015 UK time 13:41 
Of the 29 items found that appeared to be relevant, only one was applicable[1]. A Pubmed search 
for similar items yielded only 2 more, one of which was relevant [2].  
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Supplementary Material 2 
FAST Drug Management System – Hosting Requirements 
Web Server 
 Dual-Core i5 (or better), running at 2Ghz (or faster), with 8Gb of RAM and 10Gb HDD. 
Running Windows 7 and ASP.net 3.5. 
Database  
Minimum of Quad-Core i7 (or better), running at 2.4Ghz (or faster) with 16 Gb RAM, and 
1Tb HDD (preferably with RAID 10 configuration for performance and resilience). 
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